From "Going Global" to "Being Sought After": The International Appeal of Paiges Bio (02565) Innovative Assets is Taking Shape

For an innovative pharmaceutical company, the value of international collaboration has never rested solely on "how many partnerships have been signed." A more important question is: why does collaboration occur, who is seeking whom, and why are partners willing to invest their core technological platforms, R&D resources, and time into a certain group of candidate molecules. Recent developments in collaborations indicate a noteworthy change for Paige Biotechnology (02565): as the company's innovative pipeline in obesity and metabolic diseases continues to advance and the differentiated characteristics of more candidate assets gradually emerge, an increasing number of international innovation technology platforms are proactively reaching out to Paige, hoping to apply their technologies to the innovative molecules developed independently by Paige and to collaborate around new product forms and development pathways. Collaboration is not sought merely for the sake of internationalization; rather, once the assets themselves become sufficiently attractive, international collaboration begins to actively congregate around these assets. I. The consecutive international collaborations are not three isolated events From Rani Therapeutics to Lexaria Bioscience and then to SN BioScience, Paige has recently established R&D collaborations with various international innovation platforms utilizing different technological pathways. If we look at these events individually, they correspond to distinct technical directions such as oral delivery, absorption and pharmacokinetic optimization, and long-acting delivery; however, when placed on the same timeline, they actually point to a more important underlying logic: overseas platforms are continuously choosing Paige's innovative molecules to validate whether these molecules can form new product shapes under different cutting-edge technical pathways. Rani represents an innovative oral biomolecule delivery pathway, the core issue being how to overcome the limitations of traditional peptide and biomolecule administration methods; Lexaria further explores the possibilities of innovative oral delivery and pharmacokinetic optimization; SN BioScience applies its long-acting drug delivery platform to several of Paige's innovative peptide candidates, including APGP6, exploring longer durations of action, improved administration schemes, and more differentiated product forms. The three collaborations do not duplicate each other, but instead, they expand the product boundaries of the same batch of independently innovative assets from different dimensions. Thus, what is truly noteworthy is not that "Paige has gained another partner," but rather that this collaboration is demonstrating continuity: platform companies from different countries and utilizing different technological routes are willing to combine their core technologies with Paige's molecules for validation. When this choice is no longer an incidental event but begins to occur continuously, it itself constitutes a validation of the external attractiveness of the candidate assets. II. Platforms need good molecules, and quality molecules also require more product forms The commercial value of drug delivery and formulation platforms must ultimately be realized through concrete drug products. A platform may possess excellent technology, but if it lacks sufficiently competitive underlying molecules, even the best delivery technologies will struggle to marketable products. Therefore, the selection of candidate molecules for collaboration by platform companies is not a trivial technical action; it essentially reflects a judgment on the subsequent development potential, differentiation space, and commercial imagination of the candidate assets. For Paige, the significance of these collaborations is not in "borrowing others' technologies to make up for its shortcomings." On the contrary, the core of the collaboration is always Paige's own innovative molecules. What external platforms do is to further unlock new product possibilities based on these molecules: a high-quality candidate molecule need not be limited to just one dosage form, one administration frequency, or one product positioning; it can be developed into oral versions, long-acting versions, versions with different pharmacokinetic characteristics, or even a differentiated product combination targeting different patient needs through various delivery and formulation technologies. Molecules determine the upper limit of assets, while delivery technologies define the boundaries of product forms. This also means that Paige is gradually evolving from the traditional development mindset of "one molecule corresponds to one product" to a development logic of "centering on high-quality molecules and expanding multiple product forms through multiple technical platforms." For an innovative pharmaceutical company focusing on obesity and metabolic diseases, this model not only enhances the potential development value of a single molecule but also significantly increases the options available for future external collaborations. III. From technical validation to business development, international collaboration is forming a clearer gradient Early material transfers, technical validations, or joint research do not equate to formal licensing transactions and should not be simply packaged as having already realized commercial value. However, they carry important significance: they provide a low-cost, efficient preliminary validation mechanism for deeper collaboration. Only when molecules and platforms yield compelling data does the foundation for subsequent joint development, product licensing, and even commercialization partnerships become solid. Taking the collaboration with SN BioScience as an example, the collaboration is not limited to a single candidate molecule but covers multiple innovative peptide assets, including APGP6, and clearly retains the space for further discussion on licensing, joint development, and commercialization cooperation if the research results are positive. This structure itself indicates that technical validation is not the endpoint but more akin to a preliminary screening for both parties to assess whether it is worth entering the next stage of collaboration. From this perspective, the consecutive appearances of Rani, Lexaria, and SN BioScience are establishing a clearer path for Paige's international collaboration: international technology platforms proactively seek and choose promising candidate molecules, then confirm their combinatorial value through technical validation, and based on the results, decide whether to enter deeper product cooperation and business development. As more preclinical and clinical data gradually emerge, this path could become one of the important sources of global cooperation for the company in the future. IV. What is truly validated is not just the delivery technology, but the assets of Paige itself If one only looks at a single cooperation, the market may easily interpret it as an ordinary R&D event; however, as different technical platforms continue to collaborate around the candidate molecules of the same company, what investors truly need to observe is whether a form of "asset attractiveness" is being formed behind these collaborations. For Paige, the answer is gradually becoming clear: the company's candidate molecules are not only being advanced within its internal R&D system, but they are also beginning to attract external innovation technology platforms that are willing to proactively engage, invest resources, and co-validate. This is why the recent significance of international collaboration extends far beyond merely increasing a few overseas partners. More importantly, Paige is transitioning from a past in which it needed to proactively showcase its R&D capabilities to gradually allowing the assets themselves to become the entry point for collaboration. Technical platforms can originate from the United States, South Korea, or other markets, and the technological routes can vary greatly, but the core of the collaboration has not changedstill centering on Paige's independently developed innovative molecules. As more and more international technology platforms wish to apply their technologies to Paige's molecules, what is validated is not merely a specific delivery technology but the intrinsic appeal of Paige's self-innovated assets. For innovative pharmaceutical companies, this change is more crucial than simply "increasing the number of international collaborations." Because truly globally valuable assets will ultimately not rely solely on the company to tell their story; as data, differentiated characteristics, and development potential continue to be recognized, external resources will begin to converge around high-quality assets. The shift currently emerging for Paige is precisely this transition from "actively reaching out" to "an increasing number of collaborations proactively approaching."